Mark Moran

Don't Sell Celgene - Cramer's Lightning Round (7/30/08)

Cramer did lose faith in Celgene, but its giant army of loyalists who know it best did not. The near-term is absolutely brilliant, with international and label expansion of Revlimid sales, and Vidaza stealing all of Dacogen's thunder. And that's all that most investors care to hear about. But many who know the company best believe that several products in the pipeline have real potential to be far bigger even than Revlimid - starting with the next one likely to hit the market, Apremilast, which is an oral Enbrel.